Pages that link to "Q36401461"
Jump to navigation
Jump to search
The following pages link to gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand (Q36401461):
Displaying 50 items.
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin (Q24315864) (← links)
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma (Q24548019) (← links)
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 T cells (Q24621753) (← links)
- Potentiating cancer immunotherapy using an oncolytic virus (Q24628810) (← links)
- Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1 (Q24648492) (← links)
- Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10 (Q24672380) (← links)
- T-cell clonotypes in cancer (Q24803891) (← links)
- Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines (Q26738680) (← links)
- New perspectives on the role of vitiligo in immune responses to melanoma (Q26996799) (← links)
- Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing (Q27334215) (← links)
- Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope (Q27334728) (← links)
- Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide (Q27620636) (← links)
- Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts (Q27631018) (← links)
- Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides (Q27685375) (← links)
- Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies (Q28251858) (← links)
- Adoptive immunotherapy for cancer: harnessing the T cell response (Q28262548) (← links)
- Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8 T cells with low avidity (Q28360452) (← links)
- Oxidized lipids block antigen cross-presentation by dendritic cells in cancer (Q28384581) (← links)
- Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity (Q28387629) (← links)
- Quantitating T cell cross-reactivity for unrelated peptide antigens (Q28750512) (← links)
- Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy (Q30305530) (← links)
- Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy (Q30310231) (← links)
- Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity (Q30413827) (← links)
- Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen (Q30767834) (← links)
- T cell receptor specificity and mimotopes (Q31289133) (← links)
- Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines (Q33255244) (← links)
- Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. (Q33419380) (← links)
- Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens (Q33529578) (← links)
- Interplays between mouse mammary tumor virus and the cellular and humoral immune response. (Q33683433) (← links)
- Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus (Q33713083) (← links)
- Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. (Q33718633) (← links)
- Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. (Q33744525) (← links)
- Cancer therapy: new concepts on active immunization (Q33757797) (← links)
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 T cells (Q33831940) (← links)
- Rational antigen modification as a strategy to upregulate or downregulate antigen recognition (Q33840519) (← links)
- The future of interleukin-2: enhancing therapeutic anticancer vaccines (Q33844221) (← links)
- Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice (Q33898612) (← links)
- Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. (Q33942539) (← links)
- Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners (Q33945653) (← links)
- Strategies for immunotherapy of cancer (Q33957705) (← links)
- Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans (Q33959111) (← links)
- DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells (Q34001061) (← links)
- A broadly applicable approach to T cell epitope identification: Application to improving tumor associated epitopes and identifying epitopes in complex pathogens (Q34004266) (← links)
- Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity (Q34046869) (← links)
- Management of malignant melanoma: new developments in immune and gene therapy. (Q34067644) (← links)
- Therapeutic cell engineering with surface-conjugated synthetic nanoparticles (Q34112602) (← links)
- DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8 T-cell immune responses (Q34127323) (← links)
- Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. (Q34155839) (← links)
- Immunity against cancer: lessons learned from melanoma. (Q34167925) (← links)
- Hierarchy, tolerance, and dominance in the antitumor T-cell response. (Q34275036) (← links)